Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 5/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 6/20 | 0.42 |
| ▸ | MMP13 | P45452 | 6/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21773016 | 0.88 | CNR2 (0.42) | MMP9CNR2CNR1LMNAALDH1A1 | |
| SCHEMBL28282357 | 0.82 | ALDH1A1 (0.54) | MMP9CNR2CNR1LMNASMN1; SMN2 | |
| SCHEMBL19613667 | 0.81 | CNR2 (0.46) | MMP9CNR2CNR1LMNAALDH1A1 | |
| SCHEMBL19631521 | 0.80 | ACLY (0.36) | MMP9CNR2CNR1LMNAALDH1A1 | |
| SCHEMBL21772969 | 0.80 | CNR2 (0.42) | MMP9CNR2CNR1LMNASMN1; SMN2 | |
| SCHEMBL30845604 | 0.79 | CNR2 (0.42) | MMP9CNR2CNR1LMNASMN1; SMN2 | |
| SCHEMBL20476414 | 0.79 | TAS2R14 (0.60) | CNR2CNR1LMNASMN1; SMN2TAS2R14 | |
| SCHEMBL21789155 | 0.78 | CNR2 (0.41) | MMP9CNR2CNR1LMNAALDH1A1 | |
| SCHEMBL15010144 | 0.78 | CNR2 (0.41) | MMP9CNR2CNR1LMNAALDH1A1 | |
| SCHEMBL19627724 | 0.77 | MMP9 (0.37) | MMP9CNR2CNR1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-10-27 | — | — | US | disclosed |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-05-26 | — | — | US | disclosed |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2019-06-27 | — | — | US | disclosed |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | MMP9 2419/4885CNR2 304/4885CNR1 445/4885 |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | MMP9 2419/4885CNR2 304/4885CNR1 445/4885 |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | MMP9 2419/4885CNR2 304/4885CNR1 445/4885 |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | MMP9 2594/4885CNR2 347/4885CNR1 483/4885 |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | MMP9 2594/4885CNR2 347/4885CNR1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.